URMC / Research / Clinical Trials / Study Details

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Research Question:
What is the efficacy of combination chemotherapy and ruxolitinib for the treatment of B-cell acute lymphoblastic leukemia in children?

Basic Study Information

Purpose:
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Location: University of Rochester Medical Center

Lead Researcher (Principal Investigator)

Lead Researcher: Angela Girvin

Study Contact Information

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Wilmot Clinical Trials